查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1380353

基于肿瘤学的体内 CRO 市场：按服务、适应症和最终用户划分 - 全球预测 2023-2030 年

Oncology Based In-Vivo CRO Market by Services (Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies), Indication (Hematological Malignancies, Rare Cancer, Solid Tumor), End-User - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

基于肿瘤的体内 CRO 市场预计将从 2022 年的 11.5 亿美元增至 2030 年的 27 亿美元，预测期内年复合成长率为 11.24%。

基于肿瘤学的 In-Vivo CRO 的全球市场

主要市场统计
市场金额：基准年 [2022] 11.5亿美元
预计市场金额[2023] 12.7亿美元
预计市场金额[2030] 27亿美元
年复合成长率（%） 11.24%
基于肿瘤学的体内 CRO 市场-IMG1

FPNV定位矩阵

FPNV 定位矩阵是评估基于肿瘤的体内 CRO 市场的重要工具。透过分析与业务策略和产品满意度相关的关键指标来全面评估供应商。这使得使用者能够根据自己的具体资讯做出明智的决策。进阶分析将供应商分为四个像限，每个象限都有不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。这个富有洞察力的框架使决策者能够充满信心地驾驭市场。

市场占有率分析

市场占有率分析为供应商的市场形势提供了宝贵的见解。评估对整体收益、客户群和其他关键指标的影响可以全面了解公司的业绩及其面临的竞争环境。该分析还揭示了研究期间的竞争水平，例如市场占有率增长、碎片化、主导地位和行业整合。

该报告对以下几个方面提供了宝贵的见解：

1.市场渗透：提供有关市场动态和主要企业产品的全面资讯。

2. 市场开拓：详细分析新兴和成熟细分市场的渗透情况，以突显利润丰厚的商机。

3. 市场多元化：有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

5. 产品开发与创新：对未来技术、研发活动和突破性产品开发的智慧洞察。

本报告解决了以下关键问题：

1.基于肿瘤的体内CRO市场的市场规模和预测是多少？

2. 哪些产品、细分市场、应用和领域在肿瘤体内 CRO 市场中具有最高的投资潜力？

3.基于肿瘤学的体内CRO市场的竞争策略窗口是什么？

4.基于肿瘤的体内CRO市场的最新技术趋势和法律规范是什么？

5.基于肿瘤的体内CRO市场主要供应商的市场占有率是多少？

6. 进入肿瘤体内CRO市场的合适型态和策略性手段是什么？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加和有效药物研发的需求
      • 对最佳化和高效的肿瘤临床试验活动的需求日益增长
      • 政府推动个人化医疗的配合措施
    • 抑制因素
      • 资料安全和隐私问题
    • 机会
      • 透过资料分析和人工智慧，基于肿瘤学的体内技术取得进展
      • 扩大癌症领域 CRO 服务以开发生物标记
    • 任务
      • 肿瘤学临床实验中法律规章合规性的局限性
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第6章基于肿瘤的体内 CRO 市场：按服务分类

  • 生物标誌物开发
  • 临床试验管理
  • 药物动力学研究
  • 临床前研究

第7章基于肿瘤学的体内 CRO 市场（按适应症）

  • 骨髓恶性肿瘤
  • 罕见癌症
  • 固态肿瘤

第8章基于肿瘤学的体内 CRO 市场：按最终用户分类

  • 学术研究所
  • 生技公司
  • 製药公司

第9章美洲基于肿瘤的体内 CRO 市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区基于肿瘤学的体内 CRO 市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲基于肿瘤的体内 CRO 市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Altogen Labs
    • Cellvax, SAS
    • Charles River Laboratory
    • Crown Bioscience
    • Cyagen Biosciences
    • Evotec SE
    • Explicyte by Immusmol SAS Company
    • Icon PLC
    • Imavita
    • IVRS AB
    • Laboratory Corporation of America Holdings
    • Melior Discovery
    • Noble Life Sciences
    • Pharmaron
    • Pharmatest Services
    • Reaction Biology by Copeba
    • Redoxis AB
    • Taconic Biosciences, Inc.
    • The Jackson Laboratory
    • XenTech
  • 主要产品系列

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-FF012EDC38EB

The Oncology Based In-Vivo CRO Market is projected to reach USD 2.70 billion by 2030 from USD 1.15 billion in 2022, at a CAGR of 11.24% during the forecast period.

Global Oncology Based In-Vivo CRO Market

KEY MARKET STATISTICS
Base Year Value [2022] USD 1.15 billion
Estimated Year Value [2023] USD 1.27 billion
Forecast Year Value [2030] USD 2.70 billion
CAGR (%) 11.24%
Oncology Based In-Vivo CRO Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Oncology Based In-Vivo CRO Market.

Based on Services, market is studied across Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies, and Preclinical Studies. The Preclinical Studies is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Hematological Malignancies, Rare Cancer, and Solid Tumor. The Hematological Malignancies is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, and Pharmaceutical Companies. The Biotechnology Companies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Oncology Based In-Vivo CRO Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Oncology Based In-Vivo CRO Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Oncology Based In-Vivo CRO Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Oncology Based In-Vivo CRO Market?

3. What is the competitive strategic window for identifying opportunities in the Oncology Based In-Vivo CRO Market?

4. What are the latest technology trends and regulatory frameworks in the Oncology Based In-Vivo CRO Market?

5. What is the market share of the leading vendors in the Oncology Based In-Vivo CRO Market?

6. Which modes and strategic moves are suitable for entering the Oncology Based In-Vivo CRO Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Oncology Based In-Vivo CRO Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
      • 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
      • 5.1.1.3. Government initiatives encouraging personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data security and privacy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
      • 5.1.3.2. Expansion of oncology CRO services for biomarker development
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of regulatory compliance of oncology trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Oncology Based In-Vivo CRO Market, by Services

  • 6.1. Introduction
  • 6.2. Biomarker Development
  • 6.3. Clinical Trial Management
  • 6.4. Pharmacokinetics Studies
  • 6.5. Preclinical Studies

7. Oncology Based In-Vivo CRO Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematological Malignancies
  • 7.3. Rare Cancer
  • 7.4. Solid Tumor

8. Oncology Based In-Vivo CRO Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Biotechnology Companies
  • 8.4. Pharmaceutical Companies

9. Americas Oncology Based In-Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncology Based In-Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Altogen Labs
    • 13.1.2. Cellvax, SAS
    • 13.1.3. Charles River Laboratory
    • 13.1.4. Crown Bioscience
    • 13.1.5. Cyagen Biosciences
    • 13.1.6. Evotec SE
    • 13.1.7. Explicyte by Immusmol SAS Company
    • 13.1.8. Icon PLC
    • 13.1.9. Imavita
    • 13.1.10. IVRS AB
    • 13.1.11. Laboratory Corporation of America Holdings
    • 13.1.12. Melior Discovery
    • 13.1.13. Noble Life Sciences
    • 13.1.14. Pharmaron
    • 13.1.15. Pharmatest Services
    • 13.1.16. Reaction Biology by Copeba
    • 13.1.17. Redoxis AB
    • 13.1.18. Taconic Biosciences, Inc.
    • 13.1.19. The Jackson Laboratory
    • 13.1.20. XenTech
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
  • FIGURE 7. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2022 VS 2030 (%)
  • FIGURE 8. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 10. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 12. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 14. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 16. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 22. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACOKINETICS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RARE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 146. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 147. ONCOLOGY BASED IN-VIVO CRO MARKET LICENSE & PRICING